Diligence memo · auto-generated · as of July 2, 2026

Arbovax, Inc.

Arbovax, Inc. looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Arbovax, Inc. operates in Biotechnology, based in RALEIGH.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Arbovax, Inc. has raised $3.4M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $1.7M on 2010-12-31.

Most recent recorded round closed around 2014-01-20.

Valuation (modeled)modeled

Provath models Arbovax, Inc. at approximately $75M (range $1.2M–$590M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.13× the median modeled value of Seed Biotechnology companies in 2013–2015 (122 peers) — value vs value, same stage and era. Within the normal band (113% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 37 months.

Last raise 12.4 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 1.0× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 36% of Biotechnology peers (4293 compared).

Modeled value ranks above 53% of those peers.

Closest niche peers: Harpoon Medical, Inc., Admittance Technologies, Inc., Bell Biosystems, Inc., Nexstim Plc, Iontera, Inc..

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.